相关实验视频

Updated: Jul 1, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

毒素对关部疾病的有效性:系统性审查和元分析

Ravinder S Saini¹, Muhammad Ali Abdullah Almoyad², Rayan Ibrahim H Binduhayyim¹

¹Department of Dental Technology, COAMS, King Khalid University, Abha, Saudi Arabia.

|March 14, 2024

概括

与安慰剂相比,毒素 (BTX) 并没有显著降低关节疾病 (TMD) 的疼痛. 这次审查没有发现疼痛减轻,不良事件或功能结果的显著差异,表明BTX不是治疗TMD的优越治疗方法.

科学领域:

牙科牙科是指牙科的专业.
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

关节疾病 (TMDs) 涵盖了一系列影响关节和肌肉的疾病.
毒素 (BTX) 注射被探索为TMD的管理策略,但证据仍然不确.
现有的研究缺乏关于BTX对TMD疼痛和相关症状的疗效的最终结论.

研究的目的:

评估毒素 (BTX) 在减轻与关节疾病 (TMDs) 相关的疼痛方面的有效性.
为了比较BTX治疗结果与安慰剂和其他治疗TMD的干预措施.
评估二次结局,包括不良事件,最大口腔开口,口症和闭口力.

主要方法:

在PubMed,维度出版,Scopus和谷歌学者中进行了系统的文献搜索.
使用RoB 2工具评估了偏差风险,证据质量被评为低到中等.
对4项关于减轻疼痛和5项关于不良事件的研究的数据进行了元分析,将BTX与安慰剂注射进行了比较.

主要成果:

参与395名患者的4项随机对照试验 (RCT) 的元分析显示,BTX在1,3个月和6个月 (MD = -1.71, -1.53, -1.33分别) 的疼痛减少在统计学上是微不足道的.
安全性分析表明,BTX和安慰剂组在1个月和3个月后的不良事件没有统计学上显著的差异 (RR分别为1.34和1.17).
在BTX和安慰剂治疗之间,没有观察到最大口腔开口,乳头发事件或最大闭塞力方面的显著差异.

结论:

毒素 (BTX) 治疗在TMDs的疼痛减轻方面与安慰剂相比没有显著的优势.
BTX与不良事件,最大口腔开口,乳头发或闭塞力没有显著改善.
需要进一步进行高质量的随机对照试验,以阐明BTX在治疗TMD中的作用.

更多相关视频

Temporomandibular Joint Pain Measurement by Bite Force and Von Frey Filament Assays in Mice

Temporomandibular Joint Pain Measurement by Bite Force and Von Frey Filament Assays in Mice

Published on: September 13, 2024

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents

Published on: January 10, 2014

相关概念视频

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...